Rare diseases
Investigational molecules
Locations
Kungsvagen 42, Tunafors, 633 49 Eskilstuna, Sweden
Malarsjukhuset Eskilstuna in Eskilstuna, Sweden specialises in clinical trials of conditions such as Urinary tract infection, Non-small cell lung cancer, Breast cancer female, Glioblastoma, and other specialisations. This site conducts important research.
The research at Malarsjukhuset Eskilstuna focuses on patients with atrial fibrillation and advanced chronic kidney disease stage 5. The primary aim is to evaluate the effectiveness and safety of apixaban for stroke prevention, seeking to lower the risk of ischemic events while maintaining an acceptable bleeding profile.
With 10 investigators and two active studies, the department advances cardiovascular care through rigorous evaluation of novel anticoagulant strategies.
In the oncology unit, the focus is on resectable colon cancer characterized by dMMR/MSI‑H. The trial investigates peri‑operative use of dostarlimab compared with standard treatment, aiming to improve surgical outcomes and long‑term disease control.
Conducted by a team of 10 investigators, this research contributes to advancing cancer therapeutics at Malarsjukhuset Eskilstuna.
More sites in EskilstunaSweden
Clinical trials currently enrolling participants at this site.
SwedenSwedenSwedenSwedenSwedenSwedenSwedenSwedenSwedenSwedenSwedenSwedenGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
